AG-120 Racemate is primarily used in cancer research, particularly in the study of targeted therapies for certain types of leukemia and solid tumors. It functions as an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), an enzyme that is abnormally active in some cancer cells and contributes to uncontrolled cell growth. By blocking the activity of this mutant enzyme, AG-120 Racemate helps restore normal cellular differentiation processes, which can lead to reduced tumor progression. It is commonly used in preclinical studies to evaluate the efficacy and mechanism of IDH1 inhibition, supporting the development of more effective anticancer drugs. Its role as a racemic mixture also allows researchers to study the comparative activity of its enantiomers in biological systems.